Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Candel Therapeutics (CADL) has provided an update.
Candel Therapeutics, Inc. recently received Orphan Drug Designation from the FDA for their CAN-2409 drug, aimed at treating pancreatic cancer. This special status could provide developmental benefits and market exclusivity, potentially making it a noteworthy consideration for investors tracking advancements in cancer therapies and biotech sector opportunities.
For detailed information about CADL stock, go to TipRanks’ Stock Analysis page.